数据来源于沪深交易所、中证指数公司。 注：文中ETF基金均不收取销售服务费。基金费率详见各基金法律文件。 风险提示：药ETF及其联接基金被动跟踪中证制药指数，该指数基日为2011.12.30，发布日期为2013.7.15,2020-2024年分年度历史收益分别为： 41.61%、-9.10%、-21.09%、-3.70%、-6.53% ，指数成份股构成根据该指数编制规则适时调整，其回测历史业绩不预示指数未来表现。文中指 数成份股仅作展示，个股描述不作为任何形式的投资建议，也不代表管理人旗下任何基金的持仓信息和交易动向。基金管理人评估的药ETF及 其联接基金的风险等级为R3-中风险，适宜平衡型（C3）及以上投资者，适当性匹配意见请以销售机构为准。任何在本文出现的信息（包括但 不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，投资人须对任何自主决定的投资行为负责。另，本文中的 任何观点、分析及预测不构成对阅读者任何形式的投资建议，亦不对因使用本文内容所引发的直接或间接损失负任何责任。基金投资有风险， 基金的过往业绩并不代表其未来表现，基金管理人管理的其他基金的业绩并不构成基金业绩表现的保证 ...

格隆汇2月6日丨新和成(002001.SZ)涨2.04%，报28.560元，股价创历史新高，总市值877.77亿元。 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 浙江新和成股份有限公司（以下简称"公司"）于2025年8月26日召开的第九届董事会第十四次会议、 2025年9月12日召开的2025年第二次临时股东大会审议通过《关于申请注册发行债务融资工具的议 案》，同意公司向中国银行间市场交易商协会申请注册发行总额不超过30亿元（含30亿元）的银行间债 券市场非金融企业债务融资工具。 2025年12月24日，公司收到中国银行间市场交易商协会核发的《接受注册通知书》（中市协注 [2025]SCP392号、中市协注[2025]MTN1264号），中国银行间市场交易商协会同意接受公司超短期融资 券、中期票据注册，注册自通知书落款之日起2年内有效，在注册有效期内可分期发行。 公司根据自身资金计划安排和银行间市场情况，于2026年1月30日在全国银行间市场发行2026年度第一 期科技创新债券，于2026年2月3日上市流通。发行结果如下： ■ 本次债券发行的有关文件详见中国货币网（www.chinamoney.com.cn）和上海清算所 ...

浙江新和成股份有限公司 2026 年度第一期科技创新债券发行结果公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：002001 证券简称：新和成 公告编号：2026-004 2025 年 12 月 24 日，公司收到中国银行间市场交易商协会核发的《接受注 册通知书》（中市协注[2025]SCP392 号、中市协注[2025]MTN1264 号），中国 银行间市场交易商协会同意接受公司超短期融资券、中期票据注册，注册自通知 书落款之日起 2 年内有效，在注册有效期内可分期发行。 本次债券发行的有关文件详见中国货币网（www.chinamoney.com.cn）和上 海清算所（www.shclearing.com.cn）网站。 特此公告。 浙江新和成股份有限公司董事会 2026 年 2 月 4 日 浙江新和成股份有限公司（以下简称"公司"）于 2025 年 8 月 26 日召开的 第九届董事会第十四次会议、2025 年 9 月 12 日召开的 2025 年第二次临时股东 大会审议通过《关于申请注册发行债务融资工具的议案》，同意公司向中国银行 间市场交 ...

截至2026年2月3日 10:48，中证医药及医疗器械创新指数(931484)成分股方面涨跌互现，爱美客领涨 2.18%，新产业上涨1.94%，东阿阿胶上涨1.71%；海思科领跌。医疗创新ETF(516820)最新报价0.35元。 数据显示，截至2026年1月30日，中证医药及医疗器械创新指数(931484)前十大权重股分别为药明康 德、迈瑞医疗、恒瑞医药、爱尔眼科、片仔癀、新和成、华东医药、康龙化成、艾力斯、甘李药业，前 十大权重股合计占比63.9%。 风险提示：基金有风险，投资需谨慎。基金管理人承诺以诚实信用、勤勉尽责的原则管理和运用基金资 产，但不保证本基金一定盈利，也不保证最低收益。基金管理人提醒投资人基金投资的"买者自负"原 则，在做出投资决策后，基金运营状况与基金净值变化引致的投资风险，由投资人自行负担。基金的过 往业绩及其净值高低并不预示其未来业绩表现，基金管理人管理的其他基金的业绩不构成对本基金业绩 表现的保证。投资人购买基金，既可能按其持有份额分享基金投资所产生的收益，也可能承担基金投资 所带来的损失。投资人应当认真阅读《基金合同》《招募说明书》等基金法律文件，全面认识本基金的 风险收益特征 ...

Investment Rating - The industry investment rating is "Overweight," indicating an expected outperformance of the industry index relative to the benchmark by more than 5% over the next six months [66]. Core Insights - The report highlights strong price support from factories, with solid methionine prices rebounding [1]. - The average prices for various chemical products are provided, showing fluctuations in pricing and profitability across different segments [2]. - The report identifies key listed companies in the chemical sector, including Wanhua Chemical, Baofeng Energy, and others [2]. Summary by Sections 2.1 Basic Chemical Index Trends - The report includes a weekly overview of the basic chemical index trends, indicating overall market movements [10]. 2.2 Polyurethane Sector - The average prices for pure MDI, polymer MDI, and TDI are reported as 17,543, 13,864, and 14,085 CNY/ton respectively, with changes of -171, -36, and +110 CNY/ton [2]. - The gross margins for these products are 4,171, 1,493, and 2,363 CNY/ton, reflecting changes of -332, -196, and -15 CNY/ton [2]. 2.3 Oil, Coal, and Olefin Sector - Average prices for ethane, propane, thermal coal, and naphtha are reported as 1,416, 4,349, 520, and 4,074 CNY/ton respectively, with increases of +147, +52, +0, and +171 CNY/ton [2]. - The average price for polyethylene is 7,162 CNY/ton, showing a rise of +62 CNY/ton [2]. - The theoretical profits for ethane cracking, CTO, and naphtha cracking for polyethylene production are reported as 694, 1,438, and -245 CNY/ton, with respective changes of -161, +41, and -127 CNY/ton [2]. 2.4 Coal Chemical Sector - Average prices for synthetic ammonia, urea, DMF, and acetic acid are 2,184, 1,745, 3,962, and 2,579 CNY/ton respectively, with changes of -27, +5, +68, and -21 CNY/ton [2]. - The gross margins for these products are 199, 72, -92, and 445 CNY/ton, reflecting changes of -21, +1, +10, and -8 CNY/ton [2]. 2.5 Animal Nutrition Sector - Average prices for VA, VE, solid methionine, and liquid methionine are reported as 61.5, 55.1, 17.9, and 14.2 CNY/kg respectively, with changes of -0.7, +0.6, +0.3, and +0.0 CNY/kg [2].

格隆汇1月27日丨新和成(002001.SZ)在投资者互动平台表示，公司在商业航天领域的订单处于开拓市 场、稳步增长的阶段。 ...

格隆汇1月27日丨新和成(002001.SZ)在投资者互动平台表示，公司在商业航天领域的订单处于开拓市 场、稳步增长的阶段。 ...

Group 1 - The core viewpoint of the news highlights the performance of the China Medical and Medical Device Innovation Index, with notable stock movements, including a leading increase of 8.29% by Sangfor Technologies [1] - The Medical Innovation ETF has seen continuous net inflows over the past week, with a maximum single-day net inflow of 40.537 million yuan, totaling 114 million yuan [1] - A significant research breakthrough was reported regarding the oral nucleoside drug VV116, which shows promising antiviral activity against the Nipah virus, providing a potential treatment option for high-risk populations [1] Group 2 - Guosen Securities noted that the innovative drug sector exhibited significant excess returns in 2025, driven by international business development, continuous positive clinical data, and supportive policies [2] - The Medical Innovation ETF closely tracks the China Medical and Medical Device Innovation Index, which selects 30 profitable and growth-oriented companies to reflect the overall performance of the sector [2] - As of December 31, 2025, the top ten weighted stocks in the index include WuXi AppTec, Heng Rui Medicine, and Mindray Medical, collectively accounting for 63.75% of the index [2]

Core Viewpoint - The announcement details the progress of the fifth employee stock ownership plan of Zhejiang Xinhecheng Co., Ltd., including stock acquisition methods, participation details, and the relationship of participants with the company [1][2][3]. Group 1: Employee Stock Ownership Plan Implementation - The fifth employee stock ownership plan was approved by the board and shareholders, allowing the company to acquire shares through repurchase and market purchases [1]. - The plan involves repurchasing shares using a dedicated repurchase account, with a total of 21,454,310 shares transferred to the employee stock ownership plan account [3][6]. - The shares were acquired at a price of 24.19 yuan per share, with a lock-up period of 12 months starting from January 27, 2026 [6]. Group 2: Financial Details - The company has repurchased a total of 24,592,592 shares, representing 0.8002% of the total share capital, with a total expenditure of approximately 556.12 million yuan [2]. - The actual participation in the employee stock ownership plan included 602 individuals, with a total subscription amount of 25.949 million yuan, matching the approved funding amount [5]. Group 3: Participant Relationships - The actual controller and key executives of the company are involved in the employee stock ownership plan, but there is no agreement for joint action between them and the plan [7]. - The plan allows for financial support from the controlling shareholder, but it voluntarily waives voting rights associated with the shares held [7]. Group 4: Ongoing Monitoring - The company will continue to monitor the implementation of the employee stock ownership plan and fulfill its disclosure obligations as required by law [8].